Avatrombopag in Pediatric Immune Thrombocytopenia: Evidence from the AVA-PED-301 Phase 3b Trial

Highlights

• Avatrombopag achieved a durable platelet response in 28% of pediatric patients with persistent or chronic immune thrombocytopenia (ITP), compared to 0% with placebo.
• 81% of avatrombopag-treated patients showed at least two consecutive platelet responses versus none in the placebo group.
• The safety profile was reassuring, with no deaths, thromboembolic events, or severe bleeding episodes.
• Avatrombopag offers a convenient oral option with flexible administration and no dietary restrictions for children and adolescents with ITP.

Study Background and Disease Burden